Dexchlorpheniramine

CHEMBL1201353 Phase 4 Approuvé Small molecule
Half-Life
Bioavailability
Protein Binding
Molecular Weight
274.8 g/mol
LogP
3.4
Phase
4

The pharmacologically active dextrorotatory isomer of chlorpheniramine, an antihistamine used to relieve symptoms of allergic rhinitis and urticaria. It has greater antihistamine potency than the racemate.

Masse moléculaire

274,7900 g/mol

LogP

3,40

TPSA

16,10 Ų

Règle des 5 de Lipinski

Conforme

Aires thérapeutiques

Mécanisme d'action

Competitively blocks histamine H1 receptors on effector cells, preventing histamine-mediated vasodilation, increased vascular permeability, bronchoconstriction, and pruritus. First-generation agents also cross the blood-brain barrier, causing sedation.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Mécanisme

Competitively blocks histamine H1 receptors on effector cells, preventing histamine-mediated vasodilation, increased vascular permeability, bronchoconstriction, and pruritus. First-generation agents also cross the blood-brain barrier, causing sedation.

Structure 2D

SVG PNG

Cite this structure


                        

Embed this structure


                        

SMILES

CN(C)CC[C@@H](c1ccc(Cl)cc1)c1ccccn1

InChI

InChI=1S/C16H19ClN2/c1-19(2)12-10-15(16-5-3-4-11-18-16)13-6-8-14(17)9-7-13/h3-9,11,15H,10,12H2,1-2H3/t15-/m0/s1

Molecular Formula

C16H19ClN2

HBD / HBA

- / 2

Liaisons Rotatives

5

Atomes Lourds

19

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Foire aux questions

The pharmacologically active dextrorotatory isomer of chlorpheniramine, an antihistamine used to relieve symptoms of allergic rhinitis and urticaria. It has greater antihistamine potency than the racemate.

Competitively blocks histamine H1 receptors on effector cells, preventing histamine-mediated vasodilation, increased vascular permeability, bronchoconstriction, and pruritus. First-generation agents also cross the blood-brain barrier, causing sedation.

Yes, Dexchlorpheniramine is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1201353. Open-access bioactivity database.
  • PubChem — National Center for Biotechnology Information (NCBI). CID 33036. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.

Avertissement médical

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.